Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | V60E |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | MAP2K1 V60E does not lie within any known functional domains of the Map2k1 protein (UniProt.org). V60E confers a gain of function to Map2k1 as demonstrated by increased Erk signaling (PMID: 28263969), transformation activity in cultured cells and increased proliferation in a competition assay (PMID: 36442478), and tumor formation in orthotopic mouse models (PMID: 28263969), and demonstrates resistance to some Braf inhibitors (PMID: 24265153, PMID: 28263969, PMID: 36442478). |
Associated Drug Resistance | Y |
Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 V60E |
Transcript | NM_002755.4 |
gDNA | chr15:g.66435125T>A |
cDNA | c.179T>A |
Protein | p.V60E |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017022411 | chr15:g.66435125T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
XM_011521783.4 | chr15:g.66435191T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66435125T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66435125T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
NM_001411065.1 | chr15:g.66435191T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
XM_011521783 | chr15:g.66435191T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
NM_002755.4 | chr15:g.66435125T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
XM_017022412 | chr15:g.66435191T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66435125T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
XM_017022412.1 | chr15:g.66435191T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66435125T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
XM_011521783.3 | chr15:g.66435191T>A | c.179T>A | p.V60E | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 V60E | melanoma | resistant | Trametinib | Preclinical | Actionable | In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Mekinist (trametinib) in culture (PMID: 24265153). | 24265153 |
MAP2K1 V60E | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Biochemical | Actionable | In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 V60E in culture (PMID: 32641410). | 32641410 |
MAP2K1 V60E | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 V60E in culture (PMID: 36442478). | 36442478 |
MAP2K1 V60E | melanoma | resistant | Dabrafenib | Preclinical | Actionable | In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 24265153). | 24265153 |